Faruqi & Faruqi, LLP Launches An Investigation Against Cantel Medical Corp. For Potential Breaches Of Fiduciary Duties By Its Board Of Directors (CMN)

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cantel Medical Corp. (“Cantel” or the “Company”) (NYSE: CMN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval of an amendment to the Company’s Certificate of Incorporation.

Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on November 28, 2012, the Board of Directors recommends that Cantel’s shareholders vote to approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 30,000,000 to 75,000,000. The issuance of the additional shares could have a severe dilutive effect on the shares of Cantel’s common stock.

If you own common stock in Cantel and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.